HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Parlux

This article was originally published in The Rose Sheet

Executive Summary

Fragrance company will request a hearing before the Nasdaq Listing Qualifications Panel after Nasdaq informed the company that its stock is subject to delisting due to the firm's delay in filing Form 10-K for the period ended March 31, Parlux reports July 5. A possible delisting of the stock will be deferred pending the panel's review and determination, company notes. Until that time, Parlux' common stock will continue to be traded on the Nasdaq market, but the firm's trading symbol will be changed from PARL to PARLE. On June 9, Parlux filed an extension for its annual report for the fiscal year because it was unable to complete certain new requirements by the initial filing date (1"The Rose Sheet" June 19, 2006, In Brief). Shortly thereafter, Parlux CEO Ilia Lekach made an unsolicited offer to take the fragrance company private for $29 per share. However, an independent committee of the firm's board of directors responded it was not "prudent" to move forward in accepting the offer due to "significant financial and other contingencies contained in the proposal" (2"The Rose Sheet" July 3, 2006, In Brief)...

Latest Headlines
See All
UsernamePublicRestriction

Register

RS014063

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel